US FDA declines to approve Lexicon Pharma's add-on diabetes drug-May 2024-www.financetom.com

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

Dec 20, 2024 2:05 PM

Dec 20 (Reuters) - The U.S. Food and Drug Administration

declined to approve Lexicon Pharmaceuticals' ( LXRX ) add-on

drug for type 1 diabetes and chronic kidney disease, the company

said on Friday.

Previous page： Red Sea disruption cuts Q2 capacity by 15%-20%, Maersk says Next page： French cosmetics sector eyes Xi visit for reprieve on Chinese import rules

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Red Sea disruption cuts Q2 capacity by 15%-20%, Maersk says

May 6, 2024

COPENHAGEN (Reuters) - The disruption to container shipping traffic in the Red Sea is worsening, and is expected to reduce the industry's capacity between the Far East and Europe by some 15%-20% in the second quarter, shipping group Maersk said on Monday. The company, viewed as a barometer of world trade, last week said that shipping disruptions caused by Houthi...

French cosmetics sector eyes Xi visit for reprieve on Chinese import rules

May 6, 2024

By Mimosa Spencer PARIS, May 3 (Reuters) - France's world-leading cosmetics sector is counting on talks between Xi Jinping and Emmanuel Macron next week to help minimize the impact on French companies of tough new Chinese import rules requiring the sharing of formulas and manufacturing know-how. President Xi's first visit to Europe in five years comes amid a backdrop of...

Procept BioRobotics Insider Sold Shares Worth $1,916,428, According to a Recent SEC Filing

May 6, 2024

03:07 AM EDT, 05/06/2024 (MT Newswires) -- Alaleh Nouri, Executive Vice President, Chief Legal Officer, Corporate Secretary, on May 03, 2024, sold 30,432 shares in Procept BioRobotics ( PRCT ) for $1,916,428. Following the Form 4 filing with the SEC, Nouri has control over a total of 62,472 shares of the company, with 62,472 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1588978/000162828024020433/xslF345X03/wk-form4_1714786824.xml...

Procept BioRobotics Insider Sold Shares Worth $1,200,000, According to a Recent SEC Filing

May 6, 2024

03:08 AM EDT, 05/06/2024 (MT Newswires) -- Thomas M Krummel, Director, on May 01, 2024, sold 20,000 shares in Procept BioRobotics ( PRCT ) for $1,200,000. Following the Form 4 filing with the SEC, Krummel has control over a total of 45,631 shares of the company, with 45,631 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1588978/000162828024020434/xslF345X03/wk-form4_1714786884.xml Price: 65.00, Change: +0.69, Percent Change:...